Calgary-based Qualisure Diagnostics is making some serious inroads with the introduction of their flagship cancer diagnostic tool Thyroid Guide Px.

The company uses machine intelligence to create molecular tests that enhance cancer care by identifying features that help oncologists personalize treatment. By knowing  which cancers are most aggressive, and which ones are more likely to respond to certain treatments oncologists can more effectively create a personalized treatment strategy for patients.

Sit back and settle in as I talk with Dr. Oliver Bathe not only about his company's innovation but the work he's done to transition from being a medical practitioner to a full-time entrepreneur.


Bio

Oliver Bathe, Chief Executive Officer

Oliver is a surgical oncologist with over 25 years of clinical experience. He has an excellent understanding of the challenges that patients and clinicians face during their cancer journey. His research has mostly been translational in nature, applying cutting edge technological solutions to real clinical problems. 

In 2004, he founded a large tumor bank that currently houses over 23,000 samples from over 4,000 patients. His involvement in The Cancer Genome Atlas Project and his leadership in the Clinical Proteomic Analysis Consortium have spurred his interest in systems biology and bioinformatics. 

He also has experience in clinical trials, serving in leadership positions on several national and international clinical trial groups. He has directed a research program, attracting over $2 million to research related to several technologies, the majority of which have been transferred to Qualisure.

Adapted from company bio.

Shift by Alberta Innovates focuses on the people, businesses and organizations that are contributing to Alberta's strong tech ecosystem.